Does Mounjaro Affect Testosterone Levels?

The biggest myth: that weight-loss injections lower your testosterone

This concern circulates persistently in gym forums and men's health threads, and it is understandable — the idea that a medicine affecting appetite might somehow interfere with androgen production sounds plausible. The evidence does not support it. Tirzepatide has no known mechanism that would suppress testosterone. It binds to GIP and GLP-1 receptors, which are involved in insulin secretion, gastric emptying, and appetite signalling. Those pathways do not feed into the hypothalamic-pituitary-gonadal axis that governs testosterone production in men.

What tirzepatide does do, powerfully, is reduce body weight and visceral fat. Visceral fat is metabolically active; it converts androgens to oestrogens via aromatase, depresses sex hormone-binding globulin, and creates a hormonal environment that consistently suppresses free testosterone. So the net effect of successful treatment, for many men, runs in the opposite direction to the rumour. You can read more about how tirzepatide works physiologically on the tirzepatide overview page.

That said, no study has looked at testosterone as a primary endpoint in a Mounjaro trial specifically, so the evidence is largely mechanistic and extrapolated from semaglutide and general obesity-treatment data. Certainty has limits. Anyone wanting a thorough look at the question can find the full picture on our page examining whether Mounjaro lowers testosterone, and anyone with a pre-existing hormonal condition (hypogonadism, for instance) should discuss the interaction with their prescriber before starting.

What weight loss actually does to testosterone in men

The relationship between body weight and testosterone is well-established in the clinical literature. Men with obesity have, on average, substantially lower total and free testosterone than men of healthy weight. The suppression is proportional to excess fat mass, particularly fat around the abdomen and organs. When significant weight is lost (through any means, including lifestyle change, bariatric surgery, or GLP-1 receptor agonist treatment) testosterone tends to rise, sometimes substantially.

In the SURMOUNT-1 trial, participants on tirzepatide 15mg lost an average of around 20–21% of body weight over 72 weeks, based on findings published in the New England Journal of Medicine. That scale of fat loss, particularly visceral fat, is associated with clinically meaningful improvements in androgens in men with obesity. While testosterone was not a named endpoint in SURMOUNT-1, the metabolic changes tracked in the trial are exactly those that secondary research consistently links to improved male hormonal profiles.

Women are sometimes worried about the opposite, that changes in body composition might affect their own hormone balance. There is no specific evidence that tirzepatide alters oestrogen or progesterone production in women. The effect of Mounjaro on HRT is a related question with its own specific considerations, particularly around absorption of oral preparations during the early weeks of treatment.

How Mounjaro might influence blood tests that include hormonal markers

This is a practical point that matters even if the underlying hormone levels are unaffected. Mounjaro slows gastric emptying and can influence glucose metabolism in ways that affect how certain blood tests are interpreted. If you are having a hormone panel done (testosterone, SHBG, LH, FSH, prolactin, or a broader endocrine screen) your GP or specialist needs to know you are taking tirzepatide.

The wider question of how Mounjaro affects blood test results covers this territory in detail. The short version: tirzepatide can lower HbA1c and fasting glucose significantly, it can affect lipid readings, and rapid weight loss itself alters a range of biomarkers. None of this means the results are wrong, but it does mean they need context. A prescriber interpreting a testosterone result alongside a recent substantial drop in body weight will read it differently from one who does not know you have been on treatment.

There is also a question of timing. If a blood test is booked for early in the week after a weekend away, or just before a dose increase, the result may look different from one taken mid-cycle. Our clinical team encourages patients to flag their treatment status to any clinician ordering tests, so the picture is read accurately.

When to raise this with a prescriber

For most men starting Mounjaro for weight management, testosterone is unlikely to be a concern, if anything, the trajectory of evidence runs in a reassuring direction. There are, though, situations where a conversation with a prescriber is clearly the right move before starting or continuing treatment.

If you have a diagnosed testosterone deficiency and are already on testosterone replacement therapy, the interaction between TRT and tirzepatide is worth discussing explicitly. More detail on that specific question lives on the taking Mounjaro and testosterone together page. If you are experiencing symptoms that might reflect a hormonal problem (persistent fatigue, low mood, loss of libido) those warrant clinical assessment rather than attribution to any single medicine.

The NHS patient information for tirzepatide covers the known side-effect profile in full; reproductive or androgenic effects are not listed among them. For anyone wanting to understand the hormonal angle more deeply, the detailed Mounjaro and testosterone page works through the evidence at length.

Mounjaro is a prescription-only medicine. If you would like to explore whether it is clinically suitable for you, start your free consultation with our prescribers, a real clinician reviews your information the same day.